Overview

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effects of multiple-dose administration of BIA 2-093 on the steady-state pharmacokinetics of digoxin in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Digoxin
Eslicarbazepine acetate